Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2005Journal of Cerebral Blood Flow & MetabolismOpen Access

FK419 dose-dependently reduced time to first reperfusion, total occlusion time, cerebral infarction, and ameliorated neurologic deficits, whereas rt-PA reduced reperfusion time and infarction but did not significantly ameliorate neurologic deficits and induced petechial intracerebral hemorrhages.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does FK419 improve MCA patency and reduce ischemic brain damage compared to rt-PA in a primate model of thrombotic stroke?

Population

Squirrel monkeys in a thrombotic focal cerebral ischemia (stroke) model

Comparison

FK419 vs Recombinant tissue plasminogen activator (rt-PA)

Design

Preclinical

Authors

MMMasashi MaedaAMAkira MoriguchiKMKayoko Mihara

Discussion

Loading...

Member takes

Overview

Supports preclinical GPIIb/IIIa antagonist development in stroke; leaves open human translation from primate models.

Structured PICO

Does FK419 improve MCA patency and reduce ischemic brain damage compared to rt-PA in a primate model of thrombotic stroke?

P
Population
Squirrel monkeys in a thrombotic focal cerebral ischemia (stroke) model
I
Intervention
FK419 (nonpeptide platelet glycoprotein IIb/IIIa antagonist)
C
Comparator
Recombinant tissue plasminogen activator (rt-PA)
O
Outcome
Middle cerebral artery (MCA) patency (time to first reperfusion and total occlusion time) and ischemic brain damage (cerebral infarction and neurologic deficits)surrogate

In a primate stroke model, the GPIIb/IIIa antagonist FK419 restored cerebral blood flow and reduced ischemic brain injury with superior efficacy and safety compared to rt-PA.

Cite This Study

Maeda et al. (2005) studied this question.

synapsesocial.com/papers/6a74061d50d38cf5d4cdecf0https://doi.org/10.1038/sj.jcbfm.9600013
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FK419, a Novel Nonpeptide GPIIb/IIIa Antagonist, Restores Microvascular Patency and Improves Outcome in the Guinea-Pig Middle Cerebral Artery Thrombotic Occlusion Model: Comparison with Tirofiban2005 · 14 citations
  2. 2Characterization of the anti‐platelet actions of FK419, a novel non‐peptide antagonist of platelet GPIIb/IIIa2004 · 25 citations
  3. 3Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.1998 · 242 citations
  4. 4Ischemic brain tissue salvaged from infarction by the GP IIb/IIIa platelet antagonist tirofiban2002 · 36 citations
  5. 5In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography2006 · 6 citations